The use of functional assessment of coronary stenosis (following the class IA recommendation in both American and European guidelines) is below 50% in daily clinical practice. Truth be told, most operators continue having blind faith in angiography. The inclusion of coronary physiology in the decision-making process has spread widely across countries, sites, and operators. The ERIS<a href="https://solaci.org/en/2018/06/18/real-life-functional-assessment-of-coronary-stenosis-we-are-yet-to-convert-to-it/" title="Read more" >...</a>
SYNTAX I, SYNTAX II and SYNTAX III: From invasive to non-invasive assessment of Coronary Stenosis
Exhibitor: Patrick W. Serruys Recorded by TV Med – June 8th, 2016 / SOLACI-SBHCI Congress 2016. We value your opinion. You are more than welcome to leave your comments, thought, questions or suggestions here below.
Intrastent Restenosis in Ostial Lesions in the Right Coronary Artery: Predictors of an Unfavorable Location
Predictors of intrastent restenosis in the right coronary artery ostium. The ostium of the right coronary artery (RCA) presents certain histological aspects. Atherosclerotic and fibrotic plaques in this area contain an abundance of smooth muscle, collagen, and a certain degree of calcification, along with thicker adventitia. Additionally, it has certain anatomical aspects such as poor<a href="https://solaci.org/en/2023/06/16/intrastent-restenosis-in-ostial-lesions-in-the-right-coronary-artery-predictors-of-an-unfavorable-location/" title="Read more" >...</a>
Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis
3 Year Clinical Outcome Analysis and Failure Predictors in the Use of Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis In-stent restenosis (ISR) has been one of the greatest obstacles standing in the way of long term patency in percutaneous coronary interventions. However, the use of drug eluting stents (DES) and their development has helped reduce ISR<a href="https://solaci.org/en/2023/02/14/intracoronary-brachytherapy-for-drug-eluting-stent-restenosis/" title="Read more" >...</a>
What Should We Use for the Functional Assessment of Coronary Lesions in Severe Aortic Stenosis?
This systematic analysis measured intracoronary pressure in different phases of the cardiac cycle and flow velocity in patients with severe aortic stenosis and coronary artery disease, who were scheduled for transcatheter aortic valve replacement (TAVR). The aim was to determine the impact of aortic stenosis on: 1) flow, at different phases; 2) hyperemic coronary flow;<a href="https://solaci.org/en/2018/10/30/what-should-we-use-for-the-functional-assessment-of-coronary-lesions-in-severe-aortic-stenosis/" title="Read more" >...</a>
Patient Characteristics and PCI Strategies: How They Impinge on the Current Incidence of Coronary Restenosis
José Luis Leiva Pons 2012-08-08
Minimal Lumen Area Criteria for Functionally Significant Intermediate Left Main Coronary Artery Stenosis
Original title: Intravascular Ultrasound-Derived Minimal Lumen Area Criteria for Functionally Significant Left Main Coronary Artery Stenosis. Reference: Seung-Jung Park et al. J Am Coll Cardiol Intv. 2014;7(8):868-874. Deciding on a course of action when facing intermediate main left stenosis is usually challenging. We tend to overestimate the lesion or to use additional methods, other than angiography, to tip<a href="https://solaci.org/en/2014/08/21/minimal-lumen-area-criteria-for-functionally-significant-intermediate-left-main-coronary-artery-stenosis/" title="Read more" >...</a>
Strategies for treating left coronary trunk restenosis.
Original title: Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem The Milan and New-Tokyo (MITO) Registry. Reference: Circ Cardiovasc Interv. 2012;5: 491-498 We have very little data on the percutaneous treatment of restenosis of an unprotected LMCA. The aim of this study was to evaluate<a href="https://solaci.org/en/2012/12/06/strategies-for-treating-left-coronary-trunk-restenosis/" title="Read more" >...</a>
Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis
Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>
QFR Analysis of Coronary Lesions with TAVR
While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>